Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
22 March 2017
E-001897-17
Question for written answer
to the Commission
Rule 130
Liadh Ní Riada (GUE/NGL)

 Subject:  Cannabidiol for the treatment of Dravet Syndrome
 Answer(s) 

On 15 October 2014, orphan designation (EU/3/14/1339) was granted by the Commission to GW Pharma Ltd for cannabidiol for the treatment of Dravet Syndrome, a severe form of epilepsy that has a chronic debilitating effect on children and adults.

Can the Commission state whether the European Medicines Agency is currently considering making a recommendation to Member States that cannabidiol be authorised for the treatment of Dravet Syndrome through compassionate use programmes?

If not, can the Commission set out a roadmap for such a recommendation?

Last updated: 6 April 2017Legal notice